Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.54 |
| ▸ | MET | P08581 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18409684 | 0.91 | RXRA (0.49) | PTPN1METGPR84 | |
| SCHEMBL18409676 | 0.91 | RXRA (0.49) | PTPN1METGPR84 | |
| SCHEMBL18409685 | 0.90 | PTPN1 (0.46) | PTPN1METGPR84HPGDS | |
| SCHEMBL18409633 | 0.88 | PTPN1 (0.45) | PTPN1METGPR84HPGDS | |
| SCHEMBL18409575 | 0.87 | PTPN1 (0.64) | PTPN1GPR84ALDH1A1RAB9AMEN1 | |
| SCHEMBL18409571 | 0.87 | GPR84 (0.50) | PTPN1GPR84ALDH1A1RAB9AMEN1 | |
| SCHEMBL18409339 | 0.87 | HTR6 (0.52) | PTPN1GPR84ALDH1A1RAB9AMEN1 | |
| SCHEMBL18409678 | 0.85 | PTPN1 (0.57) | PTPN1GPR84ALDH1A1RAB9AMEN1 | |
| SCHEMBL18409568 | 0.85 | GPR84 (0.57) | PTPN1GPR84ALDH1A1RAB9AMEN1 | |
| SCHEMBL18409333 | 0.84 | RXRA (0.52) | PTPN1GPR84ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844051-B2 | Substituted oxazoles for the treatment of cancer | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY | 2020-11-24 | — | — | US | disclosed |
| US-20180208586-A1 | COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2018-07-26 | — | — | US | disclosed |
| WO-2017011920-A1 | COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2017-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208586-A1 | COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS | VHL, TP53, CD44 | PTPN1 2437/4885MET 1091/4885GPR84 2974/4885 |
| US-10844051-B2 | Substituted oxazoles for the treatment of cancer | OXA1L, PDCD1, MCL1 | PTPN1 839/4885MET 791/4885GPR84 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.